Finance ❯ Stock Market ❯ Market Reactions ❯ Investor Sentiment

Acquisition Impact

Biogen to Buy Apellis for $5.6 Billion in Cash, Adding Syfovre and Empaveli

Biogen aims to use Apellis’ marketed complement drugs to speed its pivot into immunology and nephrology.

IBM to Acquire Confluent for $11 Billion in All-Cash Deal